JP2022553833A5 - - Google Patents
Info
- Publication number
- JP2022553833A5 JP2022553833A5 JP2022525923A JP2022525923A JP2022553833A5 JP 2022553833 A5 JP2022553833 A5 JP 2022553833A5 JP 2022525923 A JP2022525923 A JP 2022525923A JP 2022525923 A JP2022525923 A JP 2022525923A JP 2022553833 A5 JP2022553833 A5 JP 2022553833A5
- Authority
- JP
- Japan
- Prior art keywords
- peaks
- degrees2θ
- compound
- approximately
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930153P | 2019-11-04 | 2019-11-04 | |
| US62/930,153 | 2019-11-04 | ||
| PCT/US2020/058526 WO2021091819A1 (en) | 2019-11-04 | 2020-11-02 | Salts and forms of an estrogen receptor modulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553833A JP2022553833A (ja) | 2022-12-26 |
| JP2022553833A5 true JP2022553833A5 (enExample) | 2023-11-13 |
Family
ID=75849360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525923A Pending JP2022553833A (ja) | 2019-11-04 | 2020-11-02 | エストロゲン受容体調節薬の塩及び形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220389006A1 (enExample) |
| EP (1) | EP4045507A4 (enExample) |
| JP (1) | JP2022553833A (enExample) |
| KR (1) | KR20220103977A (enExample) |
| CN (1) | CN114945570A (enExample) |
| AU (1) | AU2020380211A1 (enExample) |
| BR (1) | BR112022008520A2 (enExample) |
| CA (1) | CA3159749A1 (enExample) |
| IL (1) | IL292680A (enExample) |
| MX (1) | MX2022005139A (enExample) |
| TW (1) | TW202132294A (enExample) |
| WO (1) | WO2021091819A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2923412T3 (es) * | 2018-09-07 | 2022-09-27 | Sanofi Sa | Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas |
| CN114929696A (zh) | 2019-05-24 | 2022-08-19 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物的晶型及其制备方法和用途 |
| JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201028414A (en) * | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| PE20160874A1 (es) * | 2013-05-28 | 2016-09-04 | Astrazeneca Ab | Compuestos quimicos |
| US20190142811A1 (en) * | 2016-04-01 | 2019-05-16 | Zeno Royalties & Milestones, LLC | Estrogen receptor modulators |
| MX2022012828A (es) * | 2020-04-22 | 2023-01-04 | Recurium Ip Holdings Llc | Preparación de un degradador selectivo de receptores de estrógeno. |
-
2020
- 2020-11-02 US US17/755,562 patent/US20220389006A1/en not_active Abandoned
- 2020-11-02 BR BR112022008520A patent/BR112022008520A2/pt unknown
- 2020-11-02 CN CN202080093201.4A patent/CN114945570A/zh active Pending
- 2020-11-02 EP EP20885160.0A patent/EP4045507A4/en active Pending
- 2020-11-02 JP JP2022525923A patent/JP2022553833A/ja active Pending
- 2020-11-02 MX MX2022005139A patent/MX2022005139A/es unknown
- 2020-11-02 WO PCT/US2020/058526 patent/WO2021091819A1/en not_active Ceased
- 2020-11-02 AU AU2020380211A patent/AU2020380211A1/en active Pending
- 2020-11-02 CA CA3159749A patent/CA3159749A1/en active Pending
- 2020-11-02 KR KR1020227018944A patent/KR20220103977A/ko not_active Ceased
- 2020-11-03 TW TW109138322A patent/TW202132294A/zh unknown
-
2022
- 2022-05-02 IL IL292680A patent/IL292680A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7660040B2 (ja) | ３－（（１Ｒ，３Ｒ）－１－（２，６－ジフルオロ－４－（（１－（３－フルオロプロピル）アゼチジン－３－イル）アミノ）フェニル）－３－メチル－１，３，４，９－テトラヒドロ－２Ｈ－ピリド［３，４－ｂ］インドール－２－イル）－２，２－ジフルオロプロパン－１－オールの固体形態及び置換されたフェニル又はピリジニル部分を含む縮合三環式化合物を調製するための方法とそれらの使用方法 | |
| JP5546717B2 (ja) | アリピプラゾール結晶質形態を調製する方法 | |
| IL322447A (en) | Preparation of psilocybin, various polymorphic forms, intermediates, formulations and their use | |
| US10100032B2 (en) | Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
| JP6008937B2 (ja) | １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法 | |
| JP2016188218A (ja) | ３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）−フェノールの塩または共結晶 | |
| JP2008518904A5 (enExample) | ||
| JP2021504338A5 (enExample) | ||
| RU2007116150A (ru) | Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола | |
| JP2023511105A5 (enExample) | ||
| JP2013518041A5 (enExample) | ||
| JP2013523733A5 (enExample) | ||
| RU2013145518A (ru) | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение | |
| JP2010502767A5 (enExample) | ||
| SI3004090T1 (en) | Chemical compounds | |
| JP2015514060A5 (enExample) | ||
| JP2018504429A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| JP2013538849A5 (enExample) | ||
| TWI721947B (zh) | 抗病毒化合物的固態形式 | |
| JP2013541592A5 (enExample) | ||
| JP2012533550A5 (enExample) | ||
| US9371344B2 (en) | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | |
| WO2016054959A1 (zh) | 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法 | |
| JP2013514974A5 (enExample) |